ADC Therapeutics Ownership
| ADCT Stock | USD 3.03 0.08 2.57% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 105.4 M | Current Value 107.2 M | Avarage Shares Outstanding 74.3 M | Quarterly Volatility 19.1 M |
ADC Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. ADC Therapeutics recorded a loss per share of 1.42. The entity had not issued any dividends in recent years. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 312 people. For more info on ADC Therapeutics SA please contact Christopher Martin at 41 21 653 02 00 or go to https://www.adctherapeutics.com.Besides selling stocks to institutional investors, ADC Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ADC Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ADC Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ADC Therapeutics Quarterly Liabilities And Stockholders Equity |
|
ADC Therapeutics Insider Trades History
About 22.0% of ADC Therapeutics SA are currently held by insiders. Unlike ADC Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ADC Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ADC Therapeutics' insider trades
ADC Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ADC Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADC Therapeutics SA backward and forwards among themselves. ADC Therapeutics' institutional investor refers to the entity that pools money to purchase ADC Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2025-03-31 | 815.5 K | Ubs Group Ag | 2025-03-31 | 767.1 K | Blue Owl Capital Holdings Lp | 2025-03-31 | 733.6 K | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 692.1 K | Vanguard Group Inc | 2025-03-31 | 652 K | Northern Trust Corp | 2025-03-31 | 496.1 K | Dafna Capital Management Llc | 2025-03-31 | 224.1 K | Aqr Capital Management Llc | 2025-03-31 | 201.2 K | Charles Schwab Investment Management Inc | 2025-03-31 | 194.3 K | Redmile Group, Llc | 2025-03-31 | 15.7 M | Prosight Management, Lp | 2025-03-31 | 9.5 M |
ADC Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADC Therapeutics Outstanding Bonds
ADC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ADC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ADC bonds can be classified according to their maturity, which is the date when ADC Therapeutics SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.